Endotec Limited 04192916 false 2024-01-01 2024-12-31 2024-12-31 The principal activity of the company is that of valve and specialist engineers Digita Accounts Production Advanced 6.30.9574.0 true false false true 04192916 2024-01-01 2024-12-31 04192916 2024-12-31 04192916 bus:Director2 1 2024-12-31 04192916 bus:Director3 1 2024-12-31 04192916 bus:OrdinaryShareClass1 2024-12-31 04192916 core:RetainedEarningsAccumulatedLosses 2024-12-31 04192916 core:ShareCapital 2024-12-31 04192916 core:CurrentFinancialInstruments 2024-12-31 04192916 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 04192916 core:Non-currentFinancialInstruments core:AfterOneYear 2024-12-31 04192916 core:FurnitureFittingsToolsEquipment 2024-12-31 04192916 core:LandBuildings 2024-12-31 04192916 core:MotorVehicles 2024-12-31 04192916 bus:SmallEntities 2024-01-01 2024-12-31 04192916 bus:AuditExemptWithAccountantsReport 2024-01-01 2024-12-31 04192916 bus:FilletedAccounts 2024-01-01 2024-12-31 04192916 bus:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 04192916 bus:RegisteredOffice 2024-01-01 2024-12-31 04192916 bus:CompanySecretary1 2024-01-01 2024-12-31 04192916 bus:Director2 2024-01-01 2024-12-31 04192916 bus:Director2 1 2024-01-01 2024-12-31 04192916 bus:Director3 2024-01-01 2024-12-31 04192916 bus:Director3 1 2024-01-01 2024-12-31 04192916 bus:Director4 2024-01-01 2024-12-31 04192916 bus:OrdinaryShareClass1 2024-01-01 2024-12-31 04192916 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 04192916 core:FurnitureFittingsToolsEquipment 2024-01-01 2024-12-31 04192916 core:LandBuildings 2024-01-01 2024-12-31 04192916 core:MotorVehicles 2024-01-01 2024-12-31 04192916 core:OfficeEquipment 2024-01-01 2024-12-31 04192916 core:PlantMachinery 2024-01-01 2024-12-31 04192916 1 2024-01-01 2024-12-31 04192916 countries:England 2024-01-01 2024-12-31 04192916 2023-12-31 04192916 bus:Director2 1 2023-12-31 04192916 bus:Director3 1 2023-12-31 04192916 core:CostValuation 2023-12-31 04192916 core:FurnitureFittingsToolsEquipment 2023-12-31 04192916 core:LandBuildings 2023-12-31 04192916 core:MotorVehicles 2023-12-31 04192916 2023-01-01 2023-12-31 04192916 2023-12-31 04192916 bus:Director2 1 2023-12-31 04192916 bus:Director3 1 2023-12-31 04192916 bus:OrdinaryShareClass1 2023-12-31 04192916 core:RetainedEarningsAccumulatedLosses 2023-12-31 04192916 core:ShareCapital 2023-12-31 04192916 core:CurrentFinancialInstruments 2023-12-31 04192916 core:CurrentFinancialInstruments core:WithinOneYear 2023-12-31 04192916 core:Non-currentFinancialInstruments core:AfterOneYear 2023-12-31 04192916 core:FurnitureFittingsToolsEquipment 2023-12-31 04192916 core:LandBuildings 2023-12-31 04192916 core:MotorVehicles 2023-12-31 04192916 bus:Director2 1 2023-01-01 2023-12-31 04192916 bus:Director3 1 2023-01-01 2023-12-31 04192916 bus:Director2 1 2022-12-31 04192916 bus:Director3 1 2022-12-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 04192916

Endotec Limited

Unaudited Filleted Financial Statements

for the Year Ended 31 December 2024

 

Endotec Limited

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Unaudited Financial Statements

4 to 9

 

Endotec Limited

Company Information

Directors

S J Doe

J Doe

D Schofield

Company secretary

J Doe

Registered office

Unit E
Manby Hall Business Park
Immingham
DN40 2LT

 

Endotec Limited

(Registration number: 04192916)
Balance Sheet as at 31 December 2024

Note

2024
£

2023
£

Fixed assets

 

Tangible assets

4

131,327

132,120

Investments

5

353,056

353,056

 

484,383

485,176

Current assets

 

Stocks

6

10,000

10,000

Debtors

7

180,951

213,859

Cash at bank and in hand

 

5,481

897

 

196,432

224,756

Creditors: Amounts falling due within one year

8

(283,433)

(302,811)

Net current liabilities

 

(87,001)

(78,055)

Total assets less current liabilities

 

397,382

407,121

Creditors: Amounts falling due after more than one year

8

(83,625)

(99,945)

Provisions for liabilities

(22,530)

(17,835)

Net assets

 

291,227

289,341

Capital and reserves

 

Called up share capital

9

5,000

5,000

Retained earnings

286,227

284,341

Shareholders' funds

 

291,227

289,341

For the financial year ending 31 December 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the Company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the Directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 19 September 2025 and signed on its behalf by:
 

 

Endotec Limited

(Registration number: 04192916)
Balance Sheet as at 31 December 2024

.........................................
S J Doe
Director

.........................................
J Doe
Director

.........................................
D Schofield
Director

 

Endotec Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

1

General information

The Company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
Unit E
Manby Hall Business Park
Immingham
DN40 2LT

These financial statements were authorised for issue by the Board on 19 September 2025.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The financial statements have been prepared for the individual entity, in sterling and are rounded to the nearest pound.

Group accounts not prepared

The company is part of a small group. The company has taken advantage of the exemption provided by Section 398 of the Companies Act 2006 and has not prepared group accounts..

Going concern
The accounts have been prepared on a going concern basis.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities.

Government grants

Government grants which become receivable as compensation for expenses or losses already incurred, or for the purpose of giving immediate financial support to the entity with no future related costs, are recognised as income in the period in which they become receivable.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

Endotec Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

Deferred income tax is recognised on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements and on unused tax losses or tax credits in the Company. Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Leasehold Property

10% reducing balance

Plant & Machinery

25 % reducing balance

Fixtures and Fittings

25% reducing balance

Motor vehicles

25% reducing balance

Business combinations

Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the Company in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the Company includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.


Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stock and work in progress are valued at the lower of cost and net realisable value, after due regard for obsolete and slow moving stocks. Net realisable value is based on selling price less anticipated costs to completion and selling costs. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads.

 

Endotec Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the Company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee.

Assets held under finance leases are recognised at the lower of their fair value at inception of the lease and the present value of the minimum lease payments. These assets are depreciated on a straight-line basis over the shorter of the useful life of the asset and the lease term. The corresponding liability to the lessor is included in the balance sheet as a finance lease obligation.

Lease payments are apportioned between finance costs in the profit and loss account and reduction of the lease obligation so as to achieve a constant periodic rate of interest on the remaining balance of the liability.

Share capital

Ordinary shares are classified as equity.

Dividends

Dividend distribution to the Company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

The company contributes to certain employees personal pension schemes in accordance with statutory automatic enrolment legislation outlined under the the Pensions Act 2008. Contributions are recognised in the profit and loss account in the period in which they become payable in accordance with the rules of the scheme.

3

Staff numbers

The average number of persons employed by the Company (including Directors) during the year, was 18 (2023 - 16).

 

Endotec Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

4

Tangible assets

Land and buildings
£

Furniture, fittings and equipment
 £

Motor vehicles
 £

Total
£

Cost or valuation

At 1 January 2024

36,807

129,616

204,362

370,785

Additions

-

-

47,232

47,232

Disposals

-

-

(30,220)

(30,220)

At 31 December 2024

36,807

129,616

221,374

387,797

Depreciation

At 1 January 2024

30,968

120,317

87,380

238,665

Charge for the year

584

2,325

39,509

42,418

Eliminated on disposal

-

-

(24,613)

(24,613)

At 31 December 2024

31,552

122,642

102,276

256,470

Carrying amount

At 31 December 2024

5,255

6,974

119,098

131,327

At 31 December 2023

5,839

9,299

116,982

132,120

Included within the net book value of land and buildings above is £5,255 (2023 - £5,839) in respect of short leasehold land and buildings.
 

5

Investments

2024
£

2023
£

Investments in subsidiaries

353,056

353,056

Subsidiaries

£

Cost or valuation

At 1 January 2024

353,056

Provision

Carrying amount

At 31 December 2024

353,056

At 31 December 2023

353,056

6

Stocks

2024
£

2023
£

Finished goods and goods for resale

10,000

10,000

 

Endotec Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

7

Debtors

Current

2024
£

2023
£

Trade debtors

109,642

106,584

Amounts owed by related parties

1,651

29,173

Prepayments

35,058

33,548

Other debtors

34,600

44,554

 

180,951

213,859

8

Creditors

Creditors: amounts falling due within one year

Note

2024
£

2023
£

Due within one year

 

Loans and borrowings

165,858

154,182

Trade creditors

 

39,309

82,326

Taxation and social security

 

12,290

29,093

Accruals and deferred income

 

3,445

3,280

Other creditors

 

62,531

33,930

 

283,433

302,811

Creditors include bank loans and overdrafts and net obligations under hire purchase contracts which are secured of £225,256 (2023 - £158,990).

Creditors: amounts falling due after more than one year

Creditors include bank loans and overdrafts and net obligations under finance lease and hire purchase contracts which are secured of £83,625 (2023 - £99,945).

9

Share capital

Allotted, called up and fully paid shares

2024

2023

No.

£

No.

£

Ordinary of £1 each

5,000

5,000

5,000

5,000

       

10

Financial commitments, guarantees and contingencies

Amounts not provided for in the balance sheet

The total amount of financial commitments not included in the balance sheet is £40,000 (2023 - £52,570).

11

Related party transactions

The below advance had no fixed repayment date. Interest has been charged at the official rate.

 

Endotec Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

Transactions with Directors

2024

At 1 January 2024
£

Advances to Director
£

Repayments by Director
£

At 31 December 2024
£

J Doe

Director loan

22,277

20,023

(25,000)

17,300

S J Doe

Director loan

22,277

38,403

(43,380)

17,300

2023

At 1 January 2023
£

Advances to Director
£

Repayments by Director
£

At 31 December 2023
£

J Doe

Director loan

39,118

8,159

(25,000)

22,277

S J Doe

Director loan

39,117

31,456

(48,296)

22,277

12

Parent and ultimate parent undertaking

The Company's immediate parent is Endotec Group Limited, incorporated in England and Wales.